Abstract 908P
Background
ACC is a heterogeneous malignancy with no standard treatment for R/M disease. Around 20% of ACC carry NOTCH1 (N1) activating mutations associated with poor prognosis. We hypothesized that Ni is an active therapy for ACC pts with N1 mutation or pathway activation.
Methods
Retrospective study of 29 R/M ACC pts with N1 mutation or pathway activation (assessed by cleaved N1 IHC) treated with Ni at MD Anderson (MDA). Ni included AL101, a gamma-secretase inhibitor, or OMP-52M51, an antibody targeting N1. Efficacy endpoints were objective response rate (ORR), clinical benefit rate (CBR), and progression-free survival (PFS) per RECIST or MDA bone criteria (for pts with bone disease only). These endpoints were assessed at two timepoints: during Ni therapy and immediately prior to Ni (pre-Ni) during systemic therapy or observation for the same pts.
Results
Out of the 29 ACC pts, 18 (62%) were males with median age 45 y (26-72 y). Of 24 genotyped ACC, 23 (96%) had N1 mutation. 15 (75%) of 20 pts with reported ACC histology had a solid component. 18 (62%) pts received AL101 and 11 (38%) received OMP-52M51. Ni was given in 2nd line or beyond in 18 (62%) pts, with the most common prior regimen being platinum-based chemotherapy (55%). The ORR to Ni was 17% (5/29), CBR was 72% (21/29) and median PFS was 4.2 mos (95%CI 2.9-8.6 mos). Tumor progression on Ni occurred on non-target lesions in 10/29 (34%) pts. 23 of 29 (79%) pts were eligible for PFS analysis immediately prior to Ni; 13 (57%) had received systemic therapy and 10 (43%) were under close observation. The median PFS on Ni vs. pre-Ni was 4.2 vs. 3 mos, respectively (HR 0.42 [95%CI 0.22-0.81], p=0.0076). Considering only the 13 pts who were on systemic therapy pre-Ni, ORR pre-Ni was 0% (0/13) and CBR was 8% (1/13). Median PFS on Ni vs. prior systemic therapy was 3.7 vs. 2.1 mos, respectively (HR 0.34 [95%CI 0.13-0.93], p= 0.029).
Conclusions
Ni has activity in ACC pts with N1 mutation or pathway activation. The efficacy of Ni compares favorably with efficacy of systemic therapies administered prior to Ni. The limited PFS and high rate of tumor progression on non-target lesions suggests Ni combination therapy may be necessary to address ACC heterogeneity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The University of Texas MD Anderson Cancer Center.
Funding
Has not received any funding.
Disclosure
R. Ferrarotto: Financial Interests, Personal, Advisory Board: Regeneron-Sanofi, Ayala Pharmaceuticals, Bicara Therapeutics, Prelude Therapeutics, Guidepoint, Elevar Therapeutics, G1 Therapeutics, ExpertConnect, Remix; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Royalties: UptoDate; Financial Interests, Institutional, Coordinating PI: Merck, Gennentech, Pfizer, Ayala, EMD Serono; Financial Interests, Institutional, Other, Co-PI: Rakuten, Nanobiotix; Financial Interests, Institutional, Local PI: Prelude, ISA Therapeutics; Non-Financial Interests, Advisory Role: Cellestia. All other authors have declared no conflicts of interest.
Resources from the same session
910P - Machine learning-based survival prediction model for postoperative parotid mucoepidermoid carcinoma
Presenter: Chen Zihan
Session: Poster session 12
911P - Post-radiotherapy (RT) Epstein-Barr virus (EBV) DNA dynamics identifies optimal timepoint for stratification of high-risk nasopharyngeal carcinoma (NPC)
Presenter: Janice Ser Huey Tan
Session: Poster session 12
912P - Toripalimab in combination with anlotinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: The interim analysis of the single-arm, phase II TORAL study
Presenter: QingQing Cai
Session: Poster session 12
916P - Reducing radiation-induced temporal lobe injury by changing tumor prescription dose in nasopharyngeal carcinoma
Presenter: Xiao Xiao
Session: Poster session 12
917P - Radiation-induced nasopharyngeal necrosis in locally-recurrent nasopharyngeal carcinoma patients after re-radiotherapy
Presenter: Runda Huang
Session: Poster session 12
918P - SPP1-related M2 macrophage signatures predict prognosis and immunotherapy response in patients with nasopharyngeal carcinoma
Presenter: Li Ying
Session: Poster session 12
919P - A prognostic model of nasopharyngeal carcinoma based on 18F-FDG PET-CT radiomic parameters and clinical characteristics of patients
Presenter: Wu xi
Session: Poster session 12
920P - Envafolimab plus chemoradiotherapy for locally advanced nasopharyngeal carcinoma (NPC), a prospective, single-armed phase II trial
Presenter: Xiaohui Wang
Session: Poster session 12
921P - HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer
Presenter: Lisle Nabell
Session: Poster session 12